Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis, Inc. (Nasdaq: PSNL) announced the grant of non-qualified stock options for 35,000 shares and restricted stock units (RSUs) covering 42,100 shares to three new employees between December 5, 2022, and December 16, 2022. The grant is part of the 2020 Inducement Plan, aimed at attracting new talent to the company. The options have an exercise price of $2.83 and vest over four years. This decision aligns with Nasdaq regulations and reflects Personalis' commitment to enhancing its workforce as a leader in cancer genomics.
Personalis, Inc. (NASDAQ: PSNL) announced the retirement of CEO John West, effective December 31, 2022. West, a co-founder, has led the company since its inception in 2011, focusing on advanced cancer genomics. Aaron Tachibana, currently CFO, will serve as interim CEO, and Christopher Hall will be promoted to President. The board will search for a permanent CEO. West expressed pride in the company’s accomplishments in enhancing cancer treatments and genomic profiling.
Personalis, Inc. (NASDAQ: PSNL) has announced a collaboration with UC San Francisco (UCSF) to deploy a personalized liquid biopsy-based research assay for colorectal cancer. The NeXT Personal™ assay will evaluate ctDNA signatures linked to treatment response in late-stage patients undergoing therapy with capecitabine, pembrolizumab, and bevacizumab. This partnership aims to enhance early detection of treatment response and disease recurrence, addressing the limitations of current ctDNA assays.
Personalis, Inc. (NASDAQ: PSNL) announced it will present data from its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 8-12 in Boston. The presentation includes three abstracts that demonstrate advancements in next-generation sequencing (NGS) related to immuno-oncology. Key highlights include improved neoantigen prediction and the integration of immune infiltration metrics to enhance response predictions for immunotherapy treatments. The data aims to improve patient stratification and therapeutic efficacy.
Personalis, Inc. (Nasdaq: PSNL) reported third-quarter financial results for 2022, showing revenues of $14.9 million, down from $22.3 million in Q3 2021. Notably, revenue from biopharma customers increased by 73% to $14.9 million, driven by a $7.4 million contribution from Natera. The company announced collaborations with BC Cancer and Duke University to enhance cancer detection methods. However, net loss for the quarter was $26.5 million with a gross margin of 16.7%. The outlook for 2022 projects total revenue between $63 million and $64 million, with net loss expected between $111 million and $114 million.
Personalis, Inc. (NASDAQ: PSNL) has appointed Christopher Hall as SVP and Head of Diagnostics Business to enhance its commercial strategy. Hall joins with over 20 years in diagnostics, previously serving as CEO of Naring Health and holding executive roles at Veracyte. His past achievements include scaling Veracyte's diagnostic revenue to nearly $100 million. To facilitate his role, Personalis granted him inducement awards consisting of stock options and restricted stock units covering 500,000 shares, vesting over four years at an exercise price of $2.67 per share.
Personalis, Inc. (Nasdaq: PSNL) will release its Q3 2022 financial results on November 2, 2022. The company will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and recent highlights. Interested parties can register for the call in advance, and a live webinar will be available on the company's website. Personalis is focused on advanced genomics for precision oncology, providing insights into cancer therapies and diagnostics through its NeXT Platform, which analyzes all human genes from a single sample.
Personalis, Inc. (NASDAQ: PSNL) has partnered with Duke University and Olink Proteomics AB to research the effects of immunotherapy on advanced gastroesophageal cancer. The collaboration aims to identify composite biomarkers to enhance therapeutic decision-making. Gastroesophageal cancer is prevalent, with nearly 50% of patients facing advanced stages at diagnosis. Key goals include understanding responses to pembrolizumab, an approved immunotherapy, and developing strategies to optimize treatment effectiveness. The study will leverage Personalis' cutting-edge technology for comprehensive tumor profiling.
On September 13, 2022, at 1:30 p.m. Eastern Time, Personalis, Inc. (NASDAQ: PSNL) will present at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY. As a leader in advanced cancer genomics, Personalis offers innovative solutions for precision cancer therapies and diagnostics through its Personalis NeXT Platform. The company's Clinical Laboratory is recognized for its accuracy, quality, and efficiency, complying with industry standards.
Personalis, Inc. (NASDAQ: PSNL) announced the filing of an amended complaint against Foresight Diagnostics, claiming infringement of its newly issued US Patent No. 11,408,033. This patent strengthens Personalis' position in the molecular residual disease (MRD) testing space. The patent enables personalized MRD panels, utilizing tumor-informed and database-derived content for enhanced cancer detection. Personalis seeks injunctive relief and damages from Foresight’s alleged infringement, reinforcing its commitment to protect its intellectual property as it expands its advanced cancer genomics capabilities.